RNA Therapy Clinical Trials Market Size, Share, Trend Report 2026 to 2035
What is RNA Therapy Clinical Trials Market Size?
Global RNA Therapy Clinical Trials Market Size is valued at USD 2.57 Bn in 2025 and is predicted to reach USD 3.76 Bn by the year 2035 at a 4.0% CAGR during the forecast period for 2026 to 2035.
RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report by By Modality (RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi), By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), Region And Segment Forecasts, 2026 to 2035
RNA Therapy Clinical Trials Market Key Takeaways:
|
The process of testing and evaluating the safety and effectiveness of therapeutic interventions based on RNA molecules is referred to as RNA therapy clinical trials. RNA therapy is a large group of treatments that use various forms of RNA molecules to target and modulate gene expression, such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides. Various factors influence the market dynamics for RNA treatment clinical trials. As interest in and investment in RNA therapy has grown, so has competition among businesses developing RNA-based medications.
Established pharmaceutical businesses, as well as startups and biotech companies, entered the industry, spurring innovation and clinical trial activity. However, due to the pandemic, many active RNA treatment clinical trials were either halted or delayed. Clinical study activities were halted due to lockdowns, travel restrictions, and worries about the safety of trial participants and staff.
Competitive Landscape:
Some of the RNA Therapy Clinical Trials Market players are:
- IQVIA
- ICON Plc
- Laboratory Corporation of America Holdings
- Charles River Laboratories International, Inc.
- PAREXEL International Corp.
- Syneos Health
- Medpace Holdings, Inc.
- PPD Inc.
- Novotech
- Veristat, LLC
Market Segmentation:
The RNA Therapy Clinical Trials Market is segmented on the basis of modality, clinical trials, and therapeutic areas. Modality segment includes RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi. The clinical trials segment includes Phase I, Phase II, Phase III, and Phase IV. By therapeutic areas, the market is segmented into Rare Diseases, Anti-infective, anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular, Respiratory, Sensory, and Others.
Based On The Product, The Messenger RNA Segment Is Accounted As A Major Contributor In The RNA Therapy Clinical Trials Market
The Messenger RNA category is expected to hold a major share of the global RNA Therapy Clinical Trials Market in 2022. The COVID-19 pandemic pushed the development and deployment of mRNA-based vaccines, particularly Pfizer-BioNTech and Moderna's COVID-19 vaccines. Because of the effectiveness of these mRNA vaccines, mRNA technology has received attention and demonstrated potential in the fight against infectious diseases. Furthermore, mRNA therapies have various potential applications in a variety of disease conditions. They can be used to encode specific proteins that produce therapeutic antibodies, trigger an immune response, or restore protein function.
Phase II Segment Witnessed Growth At A Rapid Rate
The Phase II segment is projected to grow at a rapid rate in the global RNA Therapy Clinical Trials Market. Increasing R&D investment and increasing non-industry-sponsored and industry-sponsored phase II clinical studies are important contributors to the segment's growth. Phase 2 studies enable the optimal dose and dosing schedule for RNA treatments to be determined.
In The Region, The North American RNA Therapy Clinical Trials Market Holds A Significant Revenue Share
The North American RNA Therapy Clinical Trials Market is expected to report the highest market share in terms of revenue in the near future. This is due to the early acceptance of RNA therapeutics, a strong research infrastructure, a favorable regulatory environment, and a large biotechnology and pharmaceutical industry. Furthermore, numerous RNA therapies have previously acquired FDA approval, and many are currently through various phases of clinical research to demonstrate their efficacy for a variety of illnesses.
Over the projection period, Asia Pacific is expected to increase significantly. Academic institutions, research organizations, and biotech firms are actively involved in RNA-based research in countries such as China, Japan, South Korea, and Singapore, resulting in an expanding pipeline of potential RNA therapeutics and an increase in the number of clinical studies in the field.
RNA Therapy Clinical Trials Market Report Scope:
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 2.57 Bn |
| Revenue Forecast In 2035 | USD 3.76 Bn |
| Growth Rate CAGR | CAGR of 4.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Modality, Clinical Trials, And Therapeutic Areas |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
| Competitive Landscape | IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Health; Medpace Holdings, Inc.; PPD Inc.; Novotech; Veristat, LLC. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of RNA Therapy Clinical Trials Market :
RNA Therapy Clinical Trials Market, By Modality-
- RNA interference
- Antisense therapy
- Messenger RNA
- Oligonucleotide, non-antisense, non-RNAi)
RNA Therapy Clinical Trials Market, By Clinical Trials Phase-
- Phase I
- Phase II
- Phase III
- Phase IV
RNA Therapy Clinical Trials Market, By Therapeutic Areas-
- Rare Diseases
- Anti-infective
- Anticancer
- Neurological
- Alimentary/Metabolic
- Musculoskeletal
- Cardiovascular Respiratory
- Sensory
- Others
RNA Therapy Clinical Trials Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
RNA Therapy Clinical Trials Market Size is valued at USD 2.57 Bn in 2025 and is predicted to reach USD 3.76 Bn by the year 2035
RNA Therapy Clinical Trials Market expected to grow at a 4.0% CAGR during the forecast period for 2026 to 2035.
IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Health; Medpace Holdings, Inc.; PPD Inc.; Novotech; Veristat, LLC. and Other.
RNA Therapy Clinical Trials Market is segmented in Modality (RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi), By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological) and Other.
North America region is leading the RNA Therapy Clinical Trials Market.